Brief: FDA Grants Permission To Enroll Up To 8 Additional Secondary Progressive Multiple Sclerosis Patients In Expanded Access Program With Intranasal Foralumab
05/04/2022 12:06
April 5 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* FDA GRANTS PERMISSION TO ENROLL UP TO 8 ADDITIONAL
SECONDARY
PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) PATIENTS IN THE EXPANDED
ACCESS PROGRAM WITH INTRANASAL FORALUMAB
* TIZIANA LIFE SCIENCES - CLINICAL DATA UPDATE FROM SECOND
SPMS
PATIENT EXPECTED IN MAY 2022, REPRESENTING 3 MONTHS OF
INTRANASAL FORALUMAB THERAPY
Source text for Eikon: ID:nGNX317Hfl
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study